ClinicalTrials.gg
CompletedNCT01949532Updated May 2, 2017Results posted

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

A Phase 1 interventional study of Carfilzomib in Relapsed Multiple Myeloma and End-stage Renal Disease, sponsored by Amgen. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.

Sponsored by Amgen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
86th of 113
26 · median 54
Started
2014
with 9 others
Phase 1
17 of 113
2 open now
Registered
40th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 86th largest by enrollment, is one of 10 that started in 2014, is one of 17 in phase 1, and was the 40th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they respond differently to the study drug.

Read the detailed description

Specifically, the purpose of this study is to assess the influence of end-stage renal disease (ESRD) on area under the curve (both area under the curve, from time 0 to the last concentration measured [AUC0-last] and area under the curve, from time 0 extrapolated to infinity [AUC0-inf]) of carfilzomib 56 mg/m² at Cycle 2 Day 1 (C2D1) in patients with relapsed multiple myeloma.

03

Conditions studied

  • Relapsed Multiple Myeloma
  • End-stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. multiple myeloma
  2. Evaluable disease (serum protein electrophoresis [SPEP]/urine protein electrophoresis [UPEP]/serum free light chain [SFLC] criteria)
  3. Received at least 1 prior treatment regimen or for multiple myeloma
  4. End-stage renal disease (ESRD) on hemodialysis or ≥ 75 mL/min
  5. (ECOG) performance status 0 - 2
  6. Adequate organ and bone marrow function
  7. Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within the protocol-specified period prior to enrollment

Key Exclusion Criteria:

  1. Immunoglobulin M (IgM) multiple myeloma
  2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  3. Waldenström Macroglobulinemia
  4. Active congestive heart failure (NYHA Class III-IV) ischemia, conduction abnormalities
  5. Known (HIV), recent virus (HBV), virus (HCV)
  6. Myelodysplastic Syndrome
  7. to test article, constituents, or required concomitant medications
  8. Other drugs
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Normal Renal Function

    Participants with normal renal function (creatinine clearance \[CrCl\] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

  • Experimental
    End Stage Renal Disease

    Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.

    Drug: Carfilzomib

Interventions

  • Carfilzomib was administered by IV injection.

    Also known as: Kyprolis®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Carfilzomib plasma concentrations for pharmacokinetic (PK) analyses were measured by liquid chromatography with tandem mass spectrometry. The lower limit of quantitation (LLOQ) for the assay was 0.3 ng/mL.

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  2. Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  2. Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  3. Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  4. Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  5. Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  6. Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

    Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  7. Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  8. Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  9. Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  10. Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  11. Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  12. Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  13. Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  14. Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1

    Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  15. Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  16. Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  17. Maximum Observed Plasma Concentration for Metabolite PR-389/M14

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  18. Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  19. Terminal Half-life (T½) of Metabolite PR-389/M14

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  20. Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  21. Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  22. Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  23. Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  24. Terminal Half-life (T½) of Metabolite PR-413/M15

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  25. Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  26. Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  27. Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  28. Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  29. Terminal Half-life (T½) of Metabolite PR-519/M16

    Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.

  30. Number of Participants With Adverse Events (AEs)

    Determination of the severity of all adverse events was assessed following the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Fatal. A Serious AE is an AE that meets one or more of the following criteria: * Death, * Life-threatening experience; * Requires in-patient hospitalization or prolongation of an existing hospitalization, * Results in persistent or significant disability/incapacity, * Is a congenital anomaly/birth defect, * Important medical events that may not result in death, be life-threatening, or require hospitalization. Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship.

    Time frame: From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 12 October 2015; median duration of treatment was 14 weeks in the normal renal function group and 12 weeks in the ESRD group.

07

Results

Posted May 4, 2016

Participant flow

Participants were enrolled at 13 investigative study centers (6 in the United States, 2 in Canada, and 5 in Australia) from 29 January 2014 to 25 March 2015. This study is ongoing, results are reported as of the data cut-off date of 12 October 2015.

Participant flow — Overall Study
MilestoneNormal Renal FunctionEnd Stage Renal Disease
Started1511
Completed128
Not completed33
Withdrew: On-study at the data cut-off date33

Outcome measures

PrimaryArea Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2

Carfilzomib plasma concentrations for pharmacokinetic (PK) analyses were measured by liquid chromatography with tandem mass spectrometry. The lower limit of quantitation (LLOQ) for the assay was 0.3 ng/mL.

Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2563 ± 41.9747 ± 143.9
Statistical analysis
  • Normal Renal Function vs End Stage Renal Disease · Ratio of geometric means: 132.75 · 90% CI 70.60 to 249.63The point estimates of the geometric mean ratios for the PK parameters were calculated by exponentiation of the differences in the least-squares means between the renal impairment group (test) and participants with normal renal function (reference).
PrimaryArea Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2563 ± 41.8752 ± 144.7
Statistical analysis
  • Normal Renal Function vs End Stage Renal Disease · Ratio of geometric means: 133.62 · 90% CI 70.93 to 251.73
SecondaryMaximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
ng/mLNormal Renal FunctionEnd Stage Renal Disease
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 21389 ± 26.81567 ± 128.8
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
hoursNormal Renal FunctionEnd Stage Renal Disease
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 20.467 (0.250 to 0.733)0.467 (0.250 to 0.583)
SecondaryTerminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
hoursNormal Renal FunctionEnd Stage Renal Disease
Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 20.341 (0.111 to 0.498)1.25 (0.0632 to 3.31)
SecondaryClearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters/hour
Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
liters/hourNormal Renal FunctionEnd Stage Renal Disease
Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2179 ± 38.9134 ± 136.9
SecondaryMean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
hoursNormal Renal FunctionEnd Stage Renal Disease
Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 20.135 ± 62.60.245 ± 79.9
SecondaryVolume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame:
Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
litersNormal Renal FunctionEnd Stage Renal Disease
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 224.1 ± 44.832.8 ± 133.9
SecondaryArea Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1344 ± 24.8480 ± 36.0
SecondaryArea Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1347 ± 26.3479 ± 46.6
SecondaryMaximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
ng/mLNormal Renal FunctionEnd Stage Renal Disease
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1819 ± 29.81022 ± 37.2
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
hoursNormal Renal FunctionEnd Stage Renal Disease
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 10.583 (0.467 to 0.733)0.467 (0.233 to 0.750)
SecondaryTerminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
hoursNormal Renal FunctionEnd Stage Renal Disease
Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 10.387 (0.0938 to 0.599)0.992 (0.918 to 16.0)
SecondaryClearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters/hour
Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
liters/hourNormal Renal FunctionEnd Stage Renal Disease
Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1146 ± 23.093 ± 56.8
SecondaryMean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · hours
Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
hoursNormal Renal FunctionEnd Stage Renal Disease
Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 10.222 ± 16.60.426 ± 152.2
SecondaryVolume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame:
Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
litersNormal Renal FunctionEnd Stage Renal Disease
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 132.0 ± 29.753.0 ± 185.5
SecondaryArea Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)320 ± 32.81486 ± 32.3
Cycle 2, Day 1 (n = 10, 8)584 ± 17.52086 ± 132.8
SecondaryArea Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16355 ± 25.1—
Cycle 2, Day 1650 ± 22.5—
SecondaryMaximum Observed Plasma Concentration for Metabolite PR-389/M14
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration for Metabolite PR-389/M14
ng/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)153 ± 25.4413 ± 32.9
Cycle 2, Day 1 (n = 10, 8)302 ± 16.5595 ± 128.4
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)1.00 (0.750 to 1.13)1.50 (1.00 to 2.67)
Cycle 2, Day 1 (n = 10, 8)0.983 (0.583 to 1.02)2.00 (1.45 to 4.47)
SecondaryTerminal Half-life (T½) of Metabolite PR-389/M14
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Terminal Half-life (T½) of Metabolite PR-389/M14
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 161.46 (0.975 to 1.73)—
Cycle 2, Day 11.10 (0.903 to 1.70)—
SecondaryArea Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)33.4 ± 53.954.6 ± 45.0
Cycle 2, Day 1 (n = 10, 8)60.3 ± 48.486.3 ± 199.1
SecondaryArea Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 7)36.2 ± 54.166.4 ± 48.7
Cycle 2, Day 1 (n = 10, 5)63.8 ± 48.0131 ± 35.8
SecondaryMaximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15
ng/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)20.7 ± 43.525.9 ± 42.5
Cycle 2, Day 1 (n = 10, 8)40.2 ± 38.542.3 ± 163.9
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)0.833 (0.683 to 1.00)0.767 (0.733 to 1.05)
Cycle 2, Day 1 (n = 10, 8)0.667 (0.250 to 1.00)0.750 (0.717 to 1.52)
SecondaryTerminal Half-life (T½) of Metabolite PR-413/M15
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Terminal Half-life (T½) of Metabolite PR-413/M15
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 7)1.07 (0.544 to 1.33)1.41 (1.30 to 1.86)
Cycle 2, Day 1 (n = 10, 5)0.962 (0.802 to 1.21)1.37 (1.04 to 1.44)
SecondaryArea Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)82.8 ± 53.186.8 ± 44.3
Cycle 2, Day 1 (n = 10, 8)147 ± 52.8138 ± 126.6
SecondaryArea Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16
ng*h/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)84.4 ± 52.489.6 ± 42.8
Cycle 2, Day 1 (n = 10, 8)148 ± 51.7139 ± 125.1
SecondaryMaximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16
ng/mLNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)93.4 ± 40.290.4 ± 48.0
Cycle 2, Day 1 (n = 10, 8)180 ± 40.5151 ± 129.7
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)0.617 (0.467 to 1.00)0.600 (0.467 to 0.917)
Cycle 2, Day 1 (n = 10, 8)0.525 (0.250 to 0.617)0.533 (0.467 to 0.750)
SecondaryTerminal Half-life (T½) of Metabolite PR-519/M16
Time frame:
Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Terminal Half-life (T½) of Metabolite PR-519/M16
hoursNormal Renal FunctionEnd Stage Renal Disease
Cycle 1, Day 16 (n = 13, 9)0.705 (0.473 to 0.993)0.721 (0.518 to 1.42)
Cycle 2, Day 1 (n = 10, 8)0.617 (0.555 to 0.673)0.687 (0.473 to 0.933)
SecondaryNumber of Participants With Adverse Events (AEs)

Determination of the severity of all adverse events was assessed following the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Fatal. A Serious AE is an AE that meets one or more of the following criteria: * Death, * Life-threatening experience; * Requires in-patient hospitalization or prolongation of an existing hospitalization, * Results in persistent or significant disability/incapacity, * Is a congenital anomaly/birth defect, * Important medical events that may not result in death, be life-threatening, or require hospitalization. Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship.

Time frame:
From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 12 October 2015; median duration of treatment was 14 weeks in the normal renal function group and 12 weeks in the ESRD group.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsNormal Renal FunctionEnd Stage Renal Disease
Any adverse event1511
Adverse event ≥ Grade 3129
Serious adverse event109
AE leading to discontinuation of carfilzomib60
Fatal adverse events21
Treatment-related adverse events128
Treatment-related adverse event ≥ Grade 376
Serious treatment-related adverse event52
TRAE leading to discontinuation of carfilzomib40
Treatment-related fatal adverse events00

Adverse events

Collected over From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 12 October 2015; median duration of treatment was 14 weeks in the normal renal function group and 12 weeks in the ESRD group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Renal Function—10/15 (66.7%)14/15 (93.3%)
End Stage Renal Disease—9/11 (81.8%)10/11 (90.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventNormal Renal FunctionEnd Stage Renal Disease
PneumoniaInfections and infestations3/152/11
AnaemiaBlood and lymphatic system disorders0/152/11
AstheniaGeneral disorders0/152/11
PyrexiaGeneral disorders2/152/11
Lower respiratory tract infectionInfections and infestations1/152/11
HypotensionVascular disorders0/152/11
Acute kidney injuryRenal and urinary disorders2/150/11
CoagulopathyBlood and lymphatic system disorders0/151/11
Immune thrombocytopenic purpuraBlood and lymphatic system disorders0/151/11
LeukocytosisBlood and lymphatic system disorders0/151/11
Most frequent other events
Showing 10 of 169
Most frequent other events
EventNormal Renal FunctionEnd Stage Renal Disease
NauseaGastrointestinal disorders10/156/11
AnaemiaBlood and lymphatic system disorders8/155/11
FatigueGeneral disorders8/155/11
PyrexiaGeneral disorders8/152/11
ThrombocytopeniaBlood and lymphatic system disorders7/151/11
DiarrhoeaGastrointestinal disorders7/155/11
DyspnoeaRespiratory, thoracic and mediastinal disorders7/151/11
CoughRespiratory, thoracic and mediastinal disorders6/153/11
ConstipationGastrointestinal disorders2/154/11
VomitingGastrointestinal disorders3/154/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Normal Renal FunctionEnd Stage Renal DiseaseTotal
Mean64.8 ± 8.162.8 ± 7.964.0 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Normal Renal FunctionEnd Stage Renal DiseaseTotal
Female5611
Male10515
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Normal Renal FunctionEnd Stage Renal DiseaseTotal
Hispanic or Latino101
Not Hispanic or Latino14923
Unknown or Not Reported022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Normal Renal FunctionEnd Stage Renal DiseaseTotal
Asian101
Black112
White12921
Other101
Not Reported011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Normal Renal FunctionEnd Stage Renal DiseaseTotal
0 (Fully active)538
1 (Restrictive but ambulatory)10717
2 (Ambulatory but unable to work)011
08

Study locations

13 sites
  • Karmanos Cancer Institute
    Detroit, Michigan, United States
  • North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital
    Lake Success, New York, United States
  • Gabrail Cancer Center
    Canton, Ohio, United States
  • Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic
    Nashville, Tennessee, United States
  • Baylor Charles A. Sammons Cancer Center
    Dallas, Texas, United States
  • UT Southwestern Medical Center
    Dallas, Texas, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland, Australia
  • Monash Health, Monash Medical Centre
    Clayton, Victoria, Australia
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria, Australia
  • The Alfred Hospital, Malignant Haematology and Stem Cell Transplant Department
    Melbourne, Victoria, Australia
  • QEII Health Sciences Centre
    Halifax, Nova Scotia, Canada
  • Sir Mortimer B. Davis-Jewish General Hospital
    Montreal, Quebec, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2015 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2013
First posted
Sep 24, 2013
Start
Jan 2014
Primary completionActual
Apr 2015
CompletionActual
Jan 2017
Results first posted
May 4, 2016
Last update
May 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01949532
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 24, 2013
Start date
Jan 2014
Primary completion
Apr 2015
Completion
Jan 2017
Results posted
May 4, 2016
Last update
May 2, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion